Effects of dose escalating liraglutide from 1.2 to 1.8 mg in clinical practice: A case-control study

Journal of Endocrinological Investigation

Volumn 38, Issue 12, 2015, Pages 1357-1363

  Rigato, M ^a   Avogaro, A ^a   Fadini, G P ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Durability; Medications; Therapy; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; LIRAGLUTIDE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CASE CONTROL STUDY; CLINICAL PRACTICE; CONTROLLED STUDY; DIET RESTRICTION; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT RESPONSE; WEIGHT REDUCTION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; MIDDLE AGED; TREATMENT OUTCOME;

CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84946034087     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-015-0385-5     Document Type: Article

References (23)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35(6):1364-1379. doi: 10.2337/dc12-0413
2. Knudsen LB, Nielsen PF, Huusfeldt PO, Johansen NL, Madsen K, Pedersen FZ, Thogersen H, Wilken M, Agerso H (2000) Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43(9):1664-1669 (jm9909645)
3. European Medicines Agency Victoza 6 mg/ml solution for injection in pre-filled pen. http://www.medicinesorguk/EMC/medicine/21986/SPC/Victoza+6+mg+ml+solution+for+injection+in+pre-filled+pen. Accessed on 4 May 2015
4. Food and Drug Administration (2010) Victoza® [liraglutide (rDNA origin) injection], solution for subcutaneous use. https://www.accessdatafdagov/drugsatfda-docs/label/2010/022341lblpdf. Last accessed on 4 May 2015
5. Rigato M, Fadini GP (2014) Comparative effectiveness of liraglutide in the treatment of type 2 diabetes. Diabetes Metab Syndr Obes 7:107-120. doi: 10.2147/DMSO.S37644
6. Buse JB, Nauck M, Forst T, Sheu WH, Shenouda SK, Heilmann CR, Hoogwerf BJ, Gao A, Boardman MK, Fineman M, Porter L, Schernthaner G (2013) Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet 381(9861):117-124. doi: 10.1016/S0140-6736(12)61267-7
7. Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simo R (2009) Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+ SU): a randomised controlled trial. Diabetologia 52(10):2046-2055. doi: 10.1007/s00125-009-1472-y
8. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L (2009) Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 374(9683):39-47. doi: 10.1016/S0140-6736(09)60659-0
9. Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Strand J, Zdravkovic M, Le Thi TD, Colagiuri S (2009) Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 26(3):268-278. doi: 10.1111/j.1464-5491.2009.02666.x
10. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, Hale PM, Zdravkovic M, Bode B (2009) Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 373(9662):473-481. doi: 10.1016/S0140-6736(08)61246-5
11. Abdul-Ghani MA, Williams K, Kanat M, Altuntas Y, DeFronzo RA (2013) Insulin vs GLP-1 analogues in poorly controlled Type 2 diabetic subjects on oral therapy: a meta-analysis. J Endocrinol Invest 36(3):168-173. doi: 10.3275/8367
12. Barnett AH (2015) NICE draft type 2 diabetes guidelines: a cause for concern. Lancet Diabetes Endocrinol 3:403-405. doi: 10.1016/S2213-8587(15)00053-4
13. National Institute for Health and Care Excellence (NICE) Liraglutide for the treatment of type 2 diabetes mellitus. https://www.niceorguk/guidance/ta203. Accessed on 4 May 2015
14. Lapolla A, Frison V, Bettio M, Dal Pos M, Rocchini P, Panebianco G, Tadiotto F, Da Tos V, D'Ambrosio M, Marangoni A, Ferrari M, Pianta A, Balzano S, Confortin L, Lamonica M, Marin N, Strazzabosco M, Brun E, Mesturino CA, Simoncini M, Zen F, Bax G, Bonsembiante B, Cardone C, Dal Frà MG, Gallo A, Masin M, Piarulli F, Sartore G, Simioni N (2015) Correlation between baseline characteristics and clinical outcomes in a large population of diabetes patients treated with liraglutide in a real-world setting in Italy. Clin Ther 37(3):574-584. doi: 10.1016/j.clinthera.2014.11.015
15. Fadini GP, Simioni N, Frison V, Dal Pos M, Bettio M, Rocchini P, Avogaro A (2013) Independent glucose and weight-reducing effects of Liraglutide in a real-world population of type 2 diabetic outpatients. Acta Diabetol 50(6):943-949. doi: 10.1007/s00592-013-0489-3
16. Lee WC, Dekoven M, Bouchard J, Massoudi M, Langer J (2014) Improved real-world glycaemic outcomes with liraglutide versus other incretin-based therapies in type 2 diabetes. Diabetes Obes Metab 16(9):819-826. doi: 10.1111/dom.12285
17. Ponzani P (2013) Long-term effectiveness and safety of liraglutide in clinical practice. Minerva Endocrinol 38(1):103-112 (R07132039 [pii])
18. Muscogiuri G, Cignarelli A, Giorgino F, Prodram F, Santi D, Tirabassi G, Balercia G, Modica R, Faggiano A, Colao A (2014) GLP-1: benefits beyond pancreas. J Endocrinol Invest. doi: 10.1007/s40618-014-0137-y
19. Koch L (2013) Diabetes: individualized HbA(1c) targets in elderly patients with T2DM. Nat Rev Endocrinol 9(8):440. doi: 10.1038/nrendo.2013.114
20. Strain WD, Lukashevich V, Kothny W, Hoellinger MJ, Paldanius PM (2013) Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study. Lancet 382(9890):409-416. doi: 10.1016/S0140-6736(13)60995-2
21. Morley JE, Sinclair A (2013) Individualising treatment for older people with diabetes. Lancet 382(9890):378-380. doi: 10.1016/S0140-6736(13)61055-7
22. Thong K, Sen Gupta P, Cull M, Adamson K, Dove D, Rowles S, Tarpey S, Duncan C, Chalmers J, Harper R, McDonald P, Brennan U, Walton C, Ryder R, on behalf of the ABCD nationwide exenatide and liraglutide audit contributors (2014) GLP-1 receptor agonists in type 2 diabetes - NICE guidelines versus clinical practice. Br J Diabetes Vasc Dis 14:52-29
23. Esposito K, Chiodini P, Capuano A, Maiorino MI, Bellastella G, Giugliano D (2014) Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors: meta-regression analysis of 78 randomized controlled trials with 20,053 patients. Endocrine 46(1):43-51. doi: 10.1007/s12020-013-0090-0